scholarly journals Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study

2018 ◽  
Vol 7 (7) ◽  
pp. 3044-3056 ◽  
Author(s):  
Nobuaki Sato ◽  
Norikazu Masuda ◽  
Takashi Morimoto ◽  
Takayuki Ueno ◽  
Chizuko Kanbayashi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Combination Therapy ◽  
Low Dose ◽  
Phase Ii Study ◽  
Neoadjuvant Endocrine Therapy ◽  
Open Label ◽  
Estrogen Receptor Positive ◽  
Open Label Phase ◽  
Positive Breast Cancer

scholarly journals A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

2017 ◽  
Vol 163 (3) ◽  
pp. 535-544 ◽  
Author(s):  
José Baselga ◽  
Serafin M. Morales ◽  
Ahmad Awada ◽  
Joanne L. Blum ◽  
Antoinette R. Tan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology ◽  
2016 ◽  
Vol 2 (11) ◽  
pp. 1477 ◽  
Author(s):  
Laura M. Spring ◽  
Arjun Gupta ◽  
Kerry L. Reynolds ◽  
Michele A. Gadd ◽  
Leif W. Ellisen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endocrine Therapy ◽  
Neoadjuvant Endocrine Therapy ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document